VENLO, The Netherlands–(BUSINESS WIRE)–Apr 8, 2025–
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025.
Press release date / time: Wednesday, May 7, shortly after 22:05Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Thursday, May 8, at15:00 Frankfurt time / 14:00 London time / 09:00 New York time.
Three options for joining theconference call
Register for call back connection – Click here: Connect me Service is available 15 minutes before the call starts
Dial-in by phone
U.S.: +1 646 828 8193
U.S.: +1 646 828 8193
UK: +44 (0)330 165 3655
GER: +49 (0)69 6610 2480
Conference ID:
5803222
To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.
To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.
Access the audio webcast – Click here: Access Webcast
A conference call replay will be available by using the following link: https://event.webcasts.com/starthere.jsp?ei=1684140&tp_key=ac10da14a0
Contact:[email protected]
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of December 31, 2024, QIAGEN employed more than 5,700 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com.
source: QIAGEN N.V.
category: Financial
View source version on businesswire.com:https://www.businesswire.com/news/home/20250408330643/en/
CONTACT: John Gilardi
Vice President Head of Corporate Communications
+49 2103 29 11711
+49 152 018 11711
+1 240 686 2222
Email:[email protected]
Domenica Martorana
Associate Director Investor Relations
+49 2103 29 11244
+49 152 018 11244
Email:[email protected]
KEYWORD: NETHERLANDS EUROPE
INDUSTRY KEYWORD: RESEARCH FINANCE GENETICS HEALTH TECHNOLOGY PROFESSIONAL SERVICES BIOTECHNOLOGY OTHER HEALTH HEALTH SCIENCE
SOURCE: QIAGEN N.V.
Copyright Business Wire 2025.
PUB: 04/08/2025 11:22 AM/DISC: 04/08/2025 11:22 AM
http://www.businesswire.com/news/home/20250408330643/en
